BIOA · NASDAQ
BioAge Labs (BIOA) Stock Price & Fundamentals
BioAge Labs (BIOA) closed at $435.11 on Oct 9, 2026, down 0.73% from the previous close of $438.30.
Share price, past year
1Y −0.05%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $435.11 |
| Sep 30, 2026 | $436.51 |
| Aug 31, 2026 | $438.64 |
| Jul 31, 2026 | $449.05 |
| Jun 30, 2026 | $439.70 |
| May 29, 2026 | $450.30 |
| Apr 30, 2026 | $453.28 |
| Mar 31, 2026 | $457.97 |
| Feb 27, 2026 | $461.70 |
| Jan 30, 2026 | $471.85 |
| Dec 31, 2025 | $455.86 |
| Nov 28, 2025 | $448.14 |
| Oct 31, 2025 | $440.93 |
Key statistics
- Market cap
- $19.92B
- P/E (TTM)
- —
- EPS (TTM)
- −$2.38
- Revenue (TTM)
- $10.36M
- Net income (TTM)
- −$94.46M
- Shares outstanding
- 45.8M
- Dividend yield
- —
- 52-week range
- $426.29 – $474.91
BioAge Labs's market cap is $19.92B, based on a share price of $435.11 and 45.8M shares outstanding as of Jun 30, 2026.
Financials
BioAge Labs reported revenue of $9.00M for fiscal 2025.
BioAge Labs reported a net loss of $80.61M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $9.00M | — | −$80.61M | −896.1% | −$2.24 | −$82.35M |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$71.11M | — | −$6.63 | −$51.89M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $2.45M | −$26.10M | −$0.58 |
| Q1 FY2026ended Mar 31, 2026 | $2.77M | −$22.25M | −$0.52 |
| Q4 FY2025ended Dec 31, 2025 | $3.08M | −$25.94M | −$0.72 |
| Q3 FY2025ended Sep 30, 2025 | $2.05M | −$20.17M | −$0.56 |
| Q2 FY2025ended Jun 30, 2025 | $2.41M | −$21.56M | −$0.60 |
| Q1 FY2025ended Mar 31, 2025 | $1.45M | −$12.93M | −$0.36 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$23.41M | −$6.70 |
| Q2 FY2024ended Jun 30, 2024 | $0.00 | — | — |
Company profile
- Name
- BioAge Labs, Inc.
- Ticker
- BIOA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 5885 Hollis Street, Suite 370, Emeryville, CA 94608
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001709941
Recent SEC filings
- Oct 2, 2026
- Aug 5, 2026
- Aug 5, 2026
- Jun 12, 2026
- May 8, 2026
- May 8, 2026
- Mar 24, 2026
- Mar 24, 2026
Frequently asked questions
What is BioAge Labs's stock price?
BioAge Labs (BIOA) closed at $435.11 on Oct 9, 2026, down 0.73% from the previous close of $438.30.
What is BioAge Labs's market cap?
BioAge Labs's market cap is $19.92B, based on a share price of $435.11 and 45.8M shares outstanding as of Jun 30, 2026.
How much revenue does BioAge Labs make?
BioAge Labs reported revenue of $9.00M for fiscal 2025.
Does BioAge Labs pay a dividend?
BioAge Labs's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from BioAge Labs, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures